Suppr超能文献

质子治疗分配的原则与现实。

Principles and reality of proton therapy treatment allocation.

机构信息

Department of Radiation Oncology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania.

Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania; The Wharton School and Penn Medicine Center for Health Care Innovation, University of Pennsylvania, Philadelphia, Pennsylvania.

出版信息

Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):499-508. doi: 10.1016/j.ijrobp.2014.03.023. Epub 2014 May 3.

Abstract

PURPOSE

To present the principles and rationale of the Proton Priority System (PROPS), a priority points framework that assigns higher scores to patients thought to more likely benefit from proton therapy, and the distribution of PROPS scores by patient characteristics

METHODS AND MATERIALS

We performed multivariable logistic regression to evaluate the association between PROPS scores and receipt of proton therapy, adjusted for insurance status, gender, race, geography, and the domains that inform the PROPS score.

RESULTS

Among 1529 adult patients considered for proton therapy prioritization during our Center's ramp-up phase of treatment availability, PROPS scores varied by age, diagnosis, site, and other PROPS domains. In adjusted analyses, receipt of proton therapy was lower for patients with non-Medicare relative to Medicare health insurance (commercial vs Medicare: adjusted odds ratio [OR] 0.47, 95% confidence interval [CI] 0.34-0.64; managed care vs Medicare: OR 0.40, 95% CI 0.28-0.56; Medicaid vs Medicare: OR 0.24, 95% CI 0.13-0.44). Proton Priority System score and age were not significantly associated with receipt of proton therapy.

CONCLUSIONS

The Proton Priority System is a rationally designed and transparent system for allocation of proton therapy slots based on the best available evidence and expert opinion. Because the actual allocation of treatment slots depends mostly on insurance status, payers may consider incorporating PROPS, or its underlying principles, into proton therapy coverage policies.

摘要

目的

介绍质子优先系统(PROPS)的原则和基本原理,这是一种优先点框架,为那些被认为更有可能从质子治疗中获益的患者分配更高的分数,并按患者特征分布 PROPS 分数。

方法和材料

我们进行了多变量逻辑回归分析,以评估 PROPS 分数与接受质子治疗之间的关联,调整了保险状况、性别、种族、地理位置以及影响 PROPS 分数的各领域。

结果

在我们中心治疗可用性的启动阶段,有 1529 名成人患者被考虑进行质子治疗优先级排序,PROPS 分数因年龄、诊断、部位和其他 PROPS 领域而异。在调整后的分析中,与 Medicare 健康保险相比,非 Medicare 保险(商业保险与 Medicare:调整后的优势比 [OR] 0.47,95%置信区间 [CI] 0.34-0.64;管理式医疗与 Medicare:OR 0.40,95% CI 0.28-0.56;医疗补助与 Medicare:OR 0.24,95% CI 0.13-0.44)的患者接受质子治疗的可能性较低。PROPS 评分和年龄与接受质子治疗的可能性无显著相关性。

结论

质子优先系统是一种基于现有最佳证据和专家意见分配质子治疗插槽的合理设计和透明系统。由于实际治疗插槽的分配主要取决于保险状况,支付方可能会考虑将 PROPS 或其基本原理纳入质子治疗覆盖政策。

相似文献

1
Principles and reality of proton therapy treatment allocation.质子治疗分配的原则与现实。
Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):499-508. doi: 10.1016/j.ijrobp.2014.03.023. Epub 2014 May 3.
3
Insurance Approval for Proton Beam Therapy and its Impact on Delays in Treatment.保险审批对质子束治疗的影响及其对治疗延误的影响。
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):714-723. doi: 10.1016/j.ijrobp.2018.12.021. Epub 2018 Dec 14.
5
Ethical Allocation of Proton Therapy and the Insurance Review Process.质子治疗的伦理分配和保险审查流程。
Pract Radiat Oncol. 2021 Sep-Oct;11(5):e449-e458. doi: 10.1016/j.prro.2021.01.007. Epub 2021 Feb 3.
6
Insurance Authorization and Access to Proton Therapy for Patients With Head and Neck Cancers.头颈部癌症患者的保险授权与质子治疗获取情况
Int J Radiat Oncol Biol Phys. 2023 Jun 1;116(2):404-412. doi: 10.1016/j.ijrobp.2023.02.033. Epub 2023 Mar 7.

引用本文的文献

本文引用的文献

2
The proton beam debate: are facilities outstripping the evidence?质子束疗法之争:相关设施是否已超越现有证据?
J Natl Cancer Inst. 2010 Apr 7;102(7):450-3. doi: 10.1093/jnci/djq112. Epub 2010 Mar 25.
3
Principles for allocation of scarce medical interventions.稀缺医疗干预措施的分配原则。
Lancet. 2009 Jan 31;373(9661):423-31. doi: 10.1016/S0140-6736(09)60137-9.
8
Proton therapy - a systematic review of clinical effectiveness.质子治疗——临床疗效的系统评价
Radiother Oncol. 2007 May;83(2):123-32. doi: 10.1016/j.radonc.2007.03.001. Epub 2007 May 11.
9
The model for end-stage liver disease (MELD).终末期肝病模型(MELD)
Hepatology. 2007 Mar;45(3):797-805. doi: 10.1002/hep.21563.
10
Radiation therapy facilities in the United States.美国的放射治疗设施。
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1204-11. doi: 10.1016/j.ijrobp.2006.06.035.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验